Login to Your Account

In The Clinic NEWS

Heat Biologics Inc. is winding down a phase II study of its injectable adenocarcinoma cell vaccine, HS-110, in combination with low-dose cyclophosphamide, to focus instead on the potential benefits of combining the vaccine with Opdivo to battle NSCLC.

Verastem Inc. shares began climbing out of the hole dug Wednesday by Twitter wags who chastised the firm about the deaths in a phase II trial with defactinib of two late-stage lung cancer patients who "were really pretty sick in many different ways" beyond their primary disease, CEO Robert Forrester told BioWorld Today.

LONDON – Tigenix NV is claiming the crown as first to deliver positive phase III data in an allogeneic stem cell therapy, reporting statistically significant results for Cx601 in the treatment of complex perianal fistulas caused by Crohn's disease.
More In The Clinic Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: